Cargando…
Treatment with a Lactococcus lactis that chromosomally express E. coli cfaI mitigates salivary flow loss in a Sjögren’s syndrome-like disease
Sjögren’s Syndrome (SjS) results in loss of salivary and lacrimal gland excretion due to an autoimmune attack on these secretory glands. Conventional SjS treatments address the symptoms, but not the cause of disease. Recognizing this deficit of treatments to reverse SjS disease, studies were pursued...
Autores principales: | Akgul, Ali, Freguia, Christian Furlan, Maddaloni, Massimo, Hoffman, Carol, Voigt, Alexandria, Nguyen, Cuong Q., Fanger, Neil A., Fanger, Gary R., Pascual, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636062/ https://www.ncbi.nlm.nih.gov/pubmed/37945636 http://dx.doi.org/10.1038/s41598-023-46557-3 |
Ejemplares similares
-
Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjögren’s syndrome
por: Akgul, Ali, et al.
Publicado: (2021) -
Sjögren’s Syndrome Treatments in the Microbiome Era
por: Freguia, Christian Furlan, et al.
Publicado: (2023) -
Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire
por: Arukha, Ananta Prasad, et al.
Publicado: (2021) -
Delivery of IL-35 by Lactococcus lactis Ameliorates Collagen-Induced Arthritis in Mice
por: Maddaloni, Massimo, et al.
Publicado: (2018) -
The Lactococcus lactis Pan-Plasmidome
por: Kelleher, Philip, et al.
Publicado: (2019)